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702Objectives: Lymph node staging provides critical information in patients with non–small cell lung cancer
(NSCLC). Lymphangiogenesis may be an important contributor to the pathophysiology of lymphatic metasta-
ses. We hypothesized that the presence of lymph node micrometastases positively correlates with vascular en-
dothelial growth factors (VEGFs) A, C, and D as well as VEGF-receptor-3 (lymphangiogenic factors)
expression in lymph nodes.
Methods: Forty patients with NSCLC underwent preoperative positron emission tomography-computed tomog-
raphy and mediastinoscopy. Real-time polymerase chain reaction (RT-PCR) assays for messenger RNA expres-
sion of epithelial markers (ie, cytokeratin 7; carcinoembryonic antigen-related cell adhesion molecule 5;
and palate, lung, and nasal epithelium carcinoma-associated protein) were performed in selected
fluorodeoxyglucose-avid lymph nodes. VEGF-A, VEGF-C, VEGF-D, and VEGF receptor-3 expression levels
were measured in primary tumors and lymph nodes. Wilcoxon rank sum test was run for the association between
the RT-PCR epithelial marker levels and VEGF expression levels in the lymph nodes.
Results: RT-PCR for cytokeratin 7; carcinoembryonic antigen-related cell adhesion molecule 5; or palate, lung,
and nasal epithelium carcinoma-associated protein indicated lymph node micrometastatic disease in 19 of 35
patients (54%). There was a high correlation between detection of micrometastases and VEGF-A, VEGF-C,
VEGF-D, or VEGF receptor-3 expression levels in lymph nodes. Median follow-up was 12.6 months.
Conclusions:RT-PCR analysis of fluorodeoxyglucose-avid lymph nodes results in up-staging a patient’s cancer.
Micrometastases correlate with the expression of VEGF in lymph nodes in patients with NSCLC. This may re-
flect the role of lymphangiogenesis in promoting metastases. (J Thorac Cardiovasc Surg 2013;145:702-8)Lung cancer is the most frequent cause of cancer death in
both men and women in the United States and will account
for about 27% of all estimated cancer deaths in 2012.1 The
staging of lung cancer plays a critical role in efforts to com-
bat this disease. Lymph node metastasis is the most impor-
tant prognostic factor in locoregional lung cancer.
However, the accurate identification of all lymph node dis-
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The Journal of Thoracic and Cardiovascular Surgin the modest 5-year survival (73%) reported in the earliest
stage of non–small cell lung cancer (NSCLC) (denoted as
stage IA by the International Association for the Study of
Lung Cancer).2 Nearly 40% of patients who are node-
negative will develop recurrent disease and die within 2
years.3 This is believed to be due to understaging of patients’
lung cancer; that is, under-recognition of micrometastases
by standard hematoxylin and eosin (H&E) staining of lymph
nodes. Thus, better staging methods are necessary to stratify
patients, make therapeutic choices, and evaluate the effec-
tiveness of various treatment modalities in clinical trials. In-
tensive pathologic techniques such as serial sectioning,
immunohistochemistry (IHC), and real-time polymerase
chain reaction (RT-PCR) are more sensitive in detecting
these micrometastases.4-7 However, these techniques are
labor intensive and expensive. Thus, they can practically
be applied only to a limited number of lymph nodes in
each patient. Multiple techniques for sentinel lymph
node mapping have been studied as a means of selecting
a few lymph nodes per patient for detailed pathologic
analysis.8-11 Following a small 10-patient pilot study12 to in-
vestigate the feasibility of a handheld gamma probe to detectery c March 2013
Abbreviations and Acronyms
CK-7 ¼ cytokeratin 7
CEACAM5 ¼ carcinoembryonic antigen-related
cell adhesion molecule 5
FDG ¼ fluorodeoxyglucose
H&E ¼ hematoxylin and eosin
IHC ¼ immunohistochemistry
mRNA ¼ messenger RNA
NSCLC ¼ non–small cell lung cancer
PLUNC ¼ palate, lung, and nasal epithelium
carcinoma-associated protein
RT-PCR ¼ real-time polymerase chain reaction
VEGF ¼ vascular endothelial growh factor
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Slymph node fluorodeoxyglucose (FDG) avidity in patients
undergoing NSCLC surgery, we embarked on a larger study
to assess its clinical utility.
Malignant cells metastasize from the primary tumor to
other organs via either the lymphatic or vascular network.
Indeed, tumor metastasis to regional lymph nodes often rep-
resents the first step of tumor dissemination and serves as
a major prognostic indicator for the progression of human
cancers.13 Improved therapy for lung cancer requires better
fundamental understanding of the molecular mechanisms
leading to lymphatic metastasis. Lymphangiogenesis has
been suggested as an essential component in lymph node
metastasis.14-16 The vascular endothelial growth factor
(VEGF)-C/VEGF-D/VEGFR-3 axis is the best validated
signaling system for promoting lymphangiogenesis
associated with solid tumors and the metastatic spread of
tumor cells to lymph nodes.14 VEGF-A has also been shown
to influence lymphangiogenesis.17
This report focuses on the correlation of the presence of
micrometastases with VEGF-A, VEGF-C, VEGF-D, and
VEGF receptor-3 expression in the lymph nodes of a small
cohort of patients who received lymph node mapping dur-
ing their surgical resection.METHODS
Our Institutional Review Board approved a radioguided lymph node
mapping study on September 6, 2007, for 100 patients with resectable, clin-
ical stage I or II NSCLC. Individual patient consent was obtained. Ancil-
lary studies using molecular markers were written into the protocol. An
exploratory subset of 40 patients was selected for correlation of lymph
node epithelial marker expression with VEGF-A, VEGF-C, VEGF-D,
and VEGF receptor-3 expression in the same lymph nodes using reverse
transcriptase–RT-PCR techniques.
A handheld gamma probe was used to select the lymph nodes for these
assays as reported previously.12 On the day of surgery, each patient had in-
travenous injection of 10 mCi F18-FDG followed by mediastinoscopy and
anatomic lung resection if all the sampled mediastinal lymph nodes were
benign on frozen section analysis. Standard thoracoscopic or open lung re-
section, as appropriate for the individual patient’s tumor, was followed byThe Journal of Thoracic and Cacomplete thoracic lymphadenectomy. The lymph nodes were labeled using
the American Thoracic Society/Naruke lymph node map.18 All harvested
lymph nodes were scanned with the gamma probe outside the thoracic cav-
ity to measure the gamma radiation resulting from any accumulated FDG in
individual nodes. Intrathoracic radioactivity measurements were aban-
doned early in the study because of their unreliability due to interfering sig-
nals from the heart and great vessels. The resected tumor was similarly
scanned outside the thorax. We compared the radioactive signals from
the lymph nodes to each other. The FDG avid (hot) nodes had more than
twice the signal intensity of the coldest lymph node in the entire thoracic
field for that particular patient. An equal number of FDG avid (hot) and
non-FDG avid (cold) nodes were selected for detailed pathologic analysis.
All surgically removed lymph nodes were bisected and examined by
routine H&E. The selected lymph nodes that were malignant on H&E
staining required no further pathologic analysis. However, the selected
lymph nodes that were not malignant on H&E staining were subjected to
ultra-staging with multiple step sections: IHC using cytokeratin AE1/
AE3 and RT-PCR for cytokeratin 7 (CK-7); carcinoembryonic antigen-
related cell adhesion molecule 5 (CEACAM5); or palate, lung, and nasal
epithelium carcinoma associated protein (PLUNC) (epithelial markers).
These nodes were processed according to a standard protocol. After forma-
lin fixation and embedding in paraffin, step sections of each lymph node
were taken at 30 to 40 micron intervals. The sections were stained with
H&E and an average of 10 serial sections were evaluated. IHC was per-
formed with standard monoclonal mouse antihuman cytokeratin antibody
clones AE1/AE3 (Dako Inc, Carpinteria, Calif). Formalin fixed, paraffin-
embedded tissue was pretreated with proteinase K for 5 minutes. The pri-
mary antibody was diluted 1:100 and then incubated on the slides for 30
minutes. All staining steps were performed on a Dako autostainer Plus
machine (Model S3800; Dako Inc). Detection was done using the Mouse
Envisionþ system (Dako Inc). The testing was performed in a Clincal Lab-
oratory Improvement Ammendment-certified clinical laboratory using
prostate tissue as positive controls.
RNA extraction was performed on fresh primary tumors and an equal
number of FDG-avid and nonavid lymph nodes. Tissues were homoge-
nized with Trizol reagent (Invitrogen, Carlsbad, Calif). RNA was then
precipitated from the aqueous phase using isopropanol. For quality con-
trol, 260:280 ratios were examined to confirm preparation purity and an
RNA aliquot was run on an Agilent 2100 bioanalyzer (Agilent Technol-
ogies, Santa Clara, Calif) to confirm RNA integrity by generating an RNA
integrity number value. Human messenger RNAs (mRNAs) for beta
actin, CK7, VEGF-A, VEGF-C, VEGF-D, VEGF receptor-3, CEACAM5,
and PLUNC were quantified by RT-PCR-based TaqMan Gene Expression
Assays (Applied Biosystems, Foster City, Calif). The assay IDs were
respectively, Hs99999903_m1, Hs00559840_m1, Hs00900055_m1,
Hs1099203_m1, Hs01128659_m1, Hs01047677_m1, Hs00944025_m1,
and Hs00213177_m1. Briefly, random primers and reagents provided
with the High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) were used to reverse transcribe 2 mg total RNA from primary
lung tumors and lymph nodes. The complementary DNA was used as
template in 44-cycle PCR reactions on a 7900HT real-time PCR machine
(Applied Biosystems). For each reaction, the quantification cycle (Cq)
value, approximately inversely proportional to log2 value of the concen-
tration of the analyte RNA, was obtained with SDS software (version 2.3;
Applied Biosystems). The average of Cq values of triplicate PCR reac-
tions was used for analysis. Cq values for the mRNAs of interest were
normalized by subtracting the value for beta actin mRNA from them.
Beta actin is a highly conserved gene frequently used as a loading control
in PCR assays.
Descriptive statistics such as frequencies and relative frequencies were
computed for categorical variables. Numeric variables were summarized
using simple descriptive statistics such as the mean, standard deviation,
median, and range. The Wilcoxon rank sum test was used to correlate
the lymph node micrometastatic status to normalized VEGF numericrdiovascular Surgery c Volume 145, Number 3 703
TABLE 1. Patient demographic, surgical, and pathologic
characteristics
Demographic or characteristic No. of patients (N ¼ 40) %
Age (y)
Median 71
Range 52-84
Sex
Man 7 17.5
Woman 33 82.5
Clinical follow-up (mo)
Median 12.6
Range 3.7-31.6
Clinical stage
I 36 90
II 4 10
Sex
Man 7 17.5
Woman 33 82.5
Operation performed
Lobectomy 39 97.5
Pneumonectomy 1 2.5
Tumor histology
Adenocarcinoma 29 72.5
Squamous cell carcinoma 9 22.5
Adenosquamous carcinoma 1 2.5
Large cell carcinoma 1 2.5
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Svariables. Box plots were also provided to show the differences in VEGF
expression according to lymph node micrometastatic status. A 0.05 nomi-
nal significance level was used in all testing. The expression of epithelial
markers in lymph nodes was used to upstage individual patients’ cancer.
All statistical analyses were done using SAS (version 9.3; SAS Institute
Inc, Cary, NC).RESULTS
The demographic characteristics of the 40 patients in this
study are shown in Table 1. The nodal stage distribution of
patients by routine H&E, IHC, and quantitative RT-PCR are
shown in Table 2. Immunohistochemistry and RT-PCR re-
sulted in upstaging of patients’ cancer, culminating in pos-
itive stage N1 and N2 lymph nodes in 45% and 15% of
patients, respectively, by RT-PCR.
In the pathologic examination of the excised nodes, 5 pa-
tients had proven metastatic disease in the studied lymph
nodes on H&E, whereas IHC identified lymph node disease
in 2 of the 35 patients without H&E evidence for metastaticTABLE 2. Lymph node staging distribution by various modalities
Staging modality
No. of patients in stage
N0 N1 N2
Routine H & E 35 4 1
Immunohistochemistry 33 6 1
Quantitative RT-PCR 16 18 6
H & E, Hematoxylin & eosin; RT-PCR, reverse transcriptase-polymerase chain reac-
tion.
704 The Journal of Thoracic and Cardiovascular Surgdisease. The RT-PCR analysis suggested additional meta-
static disease in 19 of 35 patients (54%).
One hundred eighty-nine lymph nodes were evaluated by
RT-PCR from the 40 patients. There was a highly positive
correlation between RT-PCR detection of micrometastases
and VEGF-A, VEGF-C, VEGF-D, or VEGF receptor-3 ex-
pression levels in lymph nodes (Table 3). Box plots are also
provided to show the differences in location and scale of
VEGF expression between malignant and nonmalignant
lymph node groups (Figure 1).
There has been 1 death from disease and 2 other recur-
rences among patients who had micrometastatic disease de-
tected in their lymph nodes by RT-PCR. In the group of
patients without such disease detected in their lymph nodes,
there has been only 1 recurrence so far. The difference in the
overall and recurrence free survival between these 2 groups
has not reached statistical significance during our limited
follow-up period. This will be reassessed when the median
follow-up reaches 24 months.
DISCUSSION
Increased understanding of the complex biology of lung
cancer has led to advances in management of the disease.
Accurate staging of individual patients remains a critical
need. It guides the choice of therapy and stratifies patients
appropriately for clinical trial of novel interventions. It
also facilitates the comparison of treatment outcomes. Stan-
dard methods of evaluating thoracic lymph nodes (H&E
staining) can miss micrometastases.6,7,13,19-21 Intensive
pathologic techniques such as serial sectioning, IHC, and
RT-PCR are more sensitive in detecting these micrometa-
stases.4-7 However, these techniques are labor intensive
and expensive. Thus, they can practically be applied only
to a limited number of lymph nodes in each patient. We
used a handheld gamma probe to select lymph nodes for
measurement of the expression of mRNA for epithelial
markers by RT-PCR.
Due to the greater sensitivity of RT-PCR for micrometa-
static lymph node disease detection, we upstaged 19 of 35
patients (54%) using this technique compared with routine
pathology (H&E). This is consistent with other RT-PCR-
based studies.19,22,23 The data were reported on a per
patient basis and not a per node basis. This is because
decisions on adjuvant therapy would be based on the
presence or absence of any lymph node metastases
regardless of the number of lymph nodes involved. We
are currently assessing survival based on the presence or
absence of any micrometastatic disease in the lymph
nodes (ie, 2 groups).
Concerns have been expressed that RT-PCR may be
overly sensitive and may include false positives from meso-
thelial or endothelial cells within lymph nodes. The prog-
nostic significance of RT-PCR detection of tumor-specific
molecular markers has been shown by others.4,23,24 Weery c March 2013
TABLE 3. Association between lymph node micrometastatic status and normalized vascular endothelial growth factor (VEGF) real-time
polymerase chain reaction (RT-PCR) quantification cycles (Cqs) in lymph nodes
Normalized variable Statistic
Lymph node micrometastatic status
Overall P valueNegative Positive
VEGF-A Mean  SD 3.4  1.7 0.7  4.1 2.5  2.9 <.0001
n 148 41 189
Median 3.5 0.8 2.9
Range 2.7 to 6.5 14.1 to 3.7 14.1 to 6.5
VEGF-C Mean  SD 5.1  1.7 2.3  3.6 4.5  2.5 <.0001
n 148 41 189
Median 5.3 3.7 5
Range 0.5 to 8.3 6.9 to 6.5 6.9 to 8.3
VEGF-D Mean  SD 10.6  1.8 6.7  4.1 9.7  3 <.0001
n 148 41 189
Median 10.9 7.6 10.5
Range 5.9 to 14.3 1.5 to 13.2 1.5 to 14.3
VEGF receptor-3 Mean  SD 6.7  1.5 5.2  2.8 6.4  2 <.0025
n 148 41 189
Median 6.8 6.1 6.6
Range 2.1 to 9.8 1.1 to 10.3 1.1 to 10.3
Lower Cq values reflect higher messenger RNA expression levels. SD, Standard deviation.
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markers of interest based on literature review.4,22,23 The
positive threshold for the expression levels of these
markers in the lymph nodes was based on the minimal
expression of the same markers in primary tumors. RT-
PCR is an imperfect gold standard for the presence of lymph
node micrometastasis. Because there is no readily available
method to verify its accuracy, we have to depend on the re-
currence free survival of the 2 groups defined by the pres-
ence or absence of RT-PCR-detected nodal disease. Our
median follow-up is still relatively short (12.6 months).
Thus, it seems early to assess the survival effect of molecu-
larly detected lymph node micrometastasis in our patient
cohort. If the prognostic value of molecularly detected mi-
crometastases is proven, it would be appropriate to run clin-
ical trials to assess the benefit of adjuvant therapy in such
patients. Chemotherapy is the logical choice, but the value
of innovative intraoperative interventions, radiotherapy, and
targeted agents in such patients could be investigated.
Malignant cells metastasize from the primary tumor to
other organs via either the lymphatic or vascular network.
Indeed, tumor metastasis to regional lymph nodes often
represents the first step of tumor dissemination and serves
as a major prognostic indicator for the progression of hu-
man cancers.13 It is currently believed that lymphatics pro-
vide the major route of lung cancer metastases. However,
the exact molecular mechanisms remain unclear. There is
experimental evidence that tumors can induce the forma-
tion of new lymphatic vessels (lymphangiogenesis) even
before they metastasize to lymph nodes, and that metastas-
tic tumor cells continue to induce lymphatic vessel growth
within sentinel lymph nodes, possibly promoting their fur-
ther metastatic dissemination.14 The VEGF-C, VEGF-D,The Journal of Thoracic and Caand VEGF receptor-3 axis is the best-validated signaling
system for promoting lymphangiogenesis associated with
solid tumors and the metastatic spread of tumor cells to
lymph nodes.14 The secreted glycoproteins VEGF-C or
VEGF-D activate VEGF receptor-3, a cell surface receptor
tyrosine kinase on lymphatic endothelium, leading to
growth of lymphatic vessels.25 Overexpression of
VEGF-C and/or VEGF-D by tumor cells increases peritu-
moral and/or intratumoral lymphangiogenesis, promotes
metastasis to local lymph nodes, and may facilitate distant
organ metastasis. The role of VEGF-A in angiogenesis via
activation of its receptors, VEGF receptor-1 and VEGF
receptor-2, has been extensively documented, but it has
also been shown to influence lymphangiogenesis.17 As
a means of exploring the role of lymphangiogenesis in
the occurrence of nodal micrometastases, we measured
VEGF-A, VEGF-C, VEGF-D, and VEGF receptor-3 ex-
pression in lmph nodes. The Cq values for the mRNAs
of interest were normalized by subtracting the value for
beta actin mRNA from them (Table 3). Beta actin is
a highly conserved gene frequently used as a loading con-
trol in PCR assays. Actins are proteins that are involved in
cell motility, structure, and integrity. Thus, all the lymph
nodes were expected to express beta actin. Note that lower
Cq values reflect higher mRNA expression levels. The cor-
relation analysis was performed with the VEGF Cq values
as continuous variables and lymph node status as categor-
ical values, either positive (malignant) or negative
(nonmalignant). Our study showed a highly positive corre-
lation between the expression of VEGFs A, C, D, and
VEGF receptor-3 in lymph nodes and the presence of mi-
crometastases in those same nodes. This is consistent with
the lymphangiogenesis literature. It would be worthwhilerdiovascular Surgery c Volume 145, Number 3 705
FIGURE 1. Box plots of vascular endothelial growth factor (VEGF) expression (measured as real-time polymerase chain reaction quantification cycle
levels) grouped by lymph node micrometastatic status. Lower quantification cycle values reflect higher messenger RNA expression levels.
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Sto investigate if anti-lymphangiogenic treatment can pre-
vent lymphatic and distant metastasis of NSCLC.
Limitations of our study include the fact that not all
lymph nodes underwent IHC and RT-PCR analysis. Per-
forming such analysis on every single node would be too la-
borious and expensive. Also, our short clinical follow-up
precludes survival analysis at this time.
CONCLUSIONS
IHC and RT-PCR analysis for epithelial markers can be
used to identify patients with NSCLC with lymph node mi-
crometastatic disease. The presence of micrometastases
was associated with higher VEGF-A, VEGF-C, VGEF-D,
and VEGF receptor-3 expression in lymph nodes. The influ-
ence of these findings on survival will be determined with
further follow-up.
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DrRaphael Bueno (Boston, Mass). I would like to congratulate
you and the rest of the authors from Roswell Park on your success-
ful presentation of this work. I have a few questions. First, you note
that the gold standard kept shifting. You show that the gamma
probe approach with fludeoxyglucose (FDG) is not sufficiently ac-
curate to identify positive lymph nodes when the gold standard is
real-time polymerase chain reaction (RT-PCR), but how good was
it when the gamma probe results were compared with the poistron
emission tomography–computed tomography (PET-CT) scan or
the immunohistology of the lymph nodes?
Dr Chukwumere Nwogu (Buffalo, NY). You’re asking how
good was the gamma probe in detecting disease?
Dr Bueno. RT-PCR is not something that everybody in the
world does. What everybody in the world does is they get a PET
scan and they do histology. Sowhen you look at your gamma probe
results, you’re comparing them to known, defined things; that is,
the PET scan and the histology report. How good was it then in
terms of sensitivity, specificity, and accuracy?
Dr Nwogu. It was very sensitive in detecting disease. The
gamma probe detected activity in all the lymph nodes that were
positive using standard histology techniques. The false-positiveThe Journal of Thoracic and Carate was very high due to inflammation. That’s the challenge
with using FDG. We definitely need better radioisotopes that
will be more specific. Radioisotopes like fluorothymidine are
more specific; however, they are less sensitive. We know that
a lot of our patients have missed nodal disease, and there are re-
ports indicating a difference in survival based on the presence of
RT-PCR positive lymph nodes and negative lymph nodes.
Dr Bueno. My next question is about your patients. About
half ended up with positive lymph nodes by RT-PCR, which sug-
gests to me that most of the cases were not TNM Classification
System of Malignant Tumors (TNM) stage T1 but might have
been stage T2 or bigger T1s. If that’s true, did you stage them
up front with mediastinoscopy, or why did you choose to go
with surgery?
Dr Nwogu.We staged the disease of all these patients with me-
diastinoscopy. There were only 2 patients in our overall cohort
with positive mediastinal nodes and we did not proceed with sur-
gical resection in those cases. Most of these patients had stage T1
and T2 lesions. They all were diagnosed with clinical stage I or II
disease before surgery.
Dr Bueno. You seem to prefer RT–PCR as your gold standard
here, as we just discussed. Do you currently use it clinically, or do
you just use it as a research tool? It’s not a truly validated, worked-
out technique, as attractive as it sounds in this study.
Dr Nwogu. We are just using it for research at this point.
However, the few patients whowere diagnosed with immunohisto-
chemically positive occult disease were referred for a conversation
with a medical oncologist about getting adjuvant therapy. If we
show that there is a difference in survival between patients who
have RT–PCR-diagnosed positive nodes and those who don’t,
we have to do a clinical trial to justify adjuvant therapy.We haven’t
gotten there yet.
Dr Bueno. Finally, what this very nicely illustrates is that
RT–PCR, which is a little challenging for the pathology labs of
most hospitals, is nicely recapitulated in staining with vascular en-
dothelial growth factor (VEGF). Essentially that’s what you would
expect to do. So are you planning to move in that direction, either
to create an isotope for VEGF or have pathologists stain the nodes
for one of the VEGFs as a predictor of lymph node status?
Dr Nwogu.We haven’t done that yet, but that’s a fantastic sug-
gestion and I would definitely like to explore that.
Dr Richard J. Finley (Vancouver, BC, Canada). I would like to
ask 1 question about the size of the lymph nodes. Why were you
able to pick up so many more lymph nodes with the gamma probe
versus the regular PET–CT scan?
Dr Nwogu. I think in some ways it’s an unfair comparison be-
tween PET–CTand the gamma probe. With PET–CT scans you’re
looking at a broad view of the thorax and essentially a lot of the
lymph nodes that are in the vicinity of the primary tumor are going
to be overshadowed by the activity of the primary tumor. Most of
these patients had stage I disease. The PET–CT is most likely not
going to detect small deposits of cancer in the lymph nodes below
a threshold of 5 to 6 mm. However, the gamma probe can be put
directly on the lymph node, away from the patient. It can thus de-
tect smaller volume of disease. So by its very nature, the gamma
probe will have an advantage.
Dr Gunda Leschber (Berlin, Germany). Do you think the high
rate of positive lymph nodes could explain why somany patients inrdiovascular Surgery c Volume 145, Number 3 707
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Sthe early stages of disease do not do well in the end? The survival
rate for patients diagnosed with stage I disease is still not 100%.
Do you think that could be an explanation?
DrNwogu.Yes. It has been shown inmultiple studies, including
the recently published Z0040 study results fromAmerican College
of Surgeons Oncology Group (ACOSOG), that there is a high prev-
alence of occult metastatic lymph node disease. In that study they
showed a prevalence of 22% for occult lymph node disease, and
that was with immunohistochemistry. RT–PCR has been clearly
shown to be more sensitive, so we know that there are many pa-
tients who have occult disease. How many of them are clinically
relevant is a little bit controversial, but research has shown that
there’s a decrease in survival. So in our case the RT–PCR test
was very sensitive in detecting occult disease.
Dr Yolanda Colson (Boston, Mass). You have to be really
careful about saying that a gamma probe has increased sensitiv-
ity. What it really is, is that it has a high false-positive rate be-
cause you have shine-through from the surrounding tumor.
Those are two different concepts. It’s not really high sensitivity708 The Journal of Thoracic and Cardiovascular Surgif it spreads everywhere. Clinically we think of this spread as
false positives.
How do you know that the VEGF that you’re detecting actually
pathologically means anything? Is it truly metastasis? You’re not
seeing it any other way that you have to detect it. Does it mean any-
thing or is it just a marker of inflammation in that node or new lym-
phatic pathways, but not necessarily metastasis?
Dr Nwogu. That’s a very good question. Given the fact that we
don’t have a really good gold standard to assess RT–PCR, what we
have to rely on is the recurrence rate. Our current median follow-
up is 12.6 months. Right now, we have too few events to really see
a statistical difference in recurrence rate between the patients with
RT–PCR negative nodes and the patients with RT–PCR positive
nodes, but when we have longer follow-up and more events, we
can determine if there is a difference in recurrence between the
2 groups of patients.
The detected gamma probe radioactivity was not from shine-
through from the primary tumor. The measurements were taken
after lymph nodes were dissected away from the lung.ery c March 2013
